Gastric cancer after chemotherapy no longer gives results
Chemotherapy no longer works on my stomach cancer. What's the next step?
In gastric cancer, the next steps depend on markers such as HER2, PD-L1, MSI/MMR, and CLDN18.2, as well as on the history of previous therapy.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What changes at this stage
- Marker status may change after therapy so re-examination is sometimes discussed.
- Categories of anti-HER2 antibodies and other pathways are only relevant when markers are appropriate.
- General condition and tolerance to previous chemotherapy influence the choice.
Options that are usually discussed
Recheck markers
Re-sampling may be considered to ensure up-to-date marker status.
The next category of therapy
Targeted therapy, immunotherapy, or other combinations are discussed according to marker results.
Clinical trials and cellular therapy
Studies that screen for specific markers, including cellular therapies, may be discussed.
The decision remains with your doctor
Practical next steps
- Ensure the latest marker reports are available, including CLDN18.2 when possible.
- Ask if a network recheck is necessary.
- Assess concordance with studies that screen for the marker.
Questions for your oncologist
- Have my HER2, PD-L1, MSI/MMR, and CLDN18.2 status been checked on the latest samples?
- Would rechecking the network help at this stage?
- What is the next category of therapy worth discussing?
- Is there a clinical test that screens for my markers?
Treatment categories
Drugs commonly discussed
Clinical trials
Registry studies for this group
International-patient access and site readiness have not been verified for any study.
NCT04557969Not listedCombination regimen
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
United States1 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04557969Not verified
NCT06203600Phase 2 / Phase 3Combination regimen
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Stomach Cancer | biomarker: PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States375 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06203600Not verified
NCT06239194Phase 1 / Phase 2Combination regimen
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
United States6 registry sites
Why this appears: Appears because it is recorded for Lung Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06239194Not verified
NCT07007182Phase 2Combination regimen
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Stomach Cancer | Targeted therapy, Radiotherapy
China1 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07007182Not verified
Would you like to discuss this situation with someone?
Send a request with the context from this page so the documents and questions to prepare can be identified sooner.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Stomach Cancer
Cancer type
Reason: Has a decision situation
- CLDN18.2
Biomarker
Reason: Related through a biomarker
- HER2
Biomarker
Reason: Related through a biomarker
- Irinotecan
Drug
Reason: Related to this page
- Nivolumab
Drug
Reason: Related to this page
- Understanding clinical trials: terms, phases, and how to check early fit
Guide
Reason: Related to this page
To check
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Mungkin memerlukan
- Immunotherapy
Treatment category
Reason: Mungkin memerlukan
- Oncology intervention (interventional radiology)
Treatment category
Reason: Mungkin memerlukan
- Chemotherapy
Treatment category
Reason: Mungkin memerlukan
- Targeted therapy
Treatment category
Reason: Mungkin memerlukan
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.